Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study

Trial Profile

Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs VAC 3S (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Sponsors InnaVirVax
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Sep 2016 This trial has been completed in Germany (End date: 2016-09-01) as per European Clinical Trials Database record.
    • 23 Jun 2016 This trial was completed in Spain according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top